There are errors in [S1 Table](#pone.0212957.t001){ref-type="table"} and [S2 Table](#pone.0212957.t002){ref-type="table"}. Column name "VE (95%CI)" in [S1 Table](#pone.0212957.t001){ref-type="table"} should be "VE in % (95%CI)." Column name "reference pre-period IR" in [S2 Table](#pone.0212957.t002){ref-type="table"} should be "reference pre-period IR/10^6^."
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###### Vaccine effectiveness of the childhood 2+1 PCV10 program among \<5, and the age-subgroup \<2 years, estimated by pre-post rate comparison, and among the ≥50 and age-subgroup ≥60 years, estimated by the segmented time series regression analysis, Austria, January, 2009-February, 2017.
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  Age-group   Outcome category   IPD by ST       VE in % (95%CI)
  ----------- ------------------ --------------- -----------------
  \<5         Intervention       PCV10 ST-IPD    58 (30; 74)
              Net change I       serotyped IPD   33 (8; 51)
              Net change II      overall IPD     35 (15; 50)
  \<2         Intervention       PCV10 ST-IPD    77 (53; 89)
              Net change I       serotyped IPD   53 (27;69)
              Net change II      overall IPD     48 (25; 64)
  ≥50         Intervention       PCV10 ST-IPD    67 (32; 84)
              Net change I       serotyped IPD   52 (10; 74)
              Net change II      overall IPD     51 (8; 74)
  ≥60         Intervention       PCV10 ST-IPD    71 (36; 88)
              Net change I       serotyped IPD   51 (3; 76)
              Net change II      overall IPD     49 (-1; 75)

°For the age groups 2--4, 5--49 and 50--59 years old no protective vaccine effect was detected

10.1371/journal.pone.0212957.t002

###### Serotype-specific analyses: monthly average incidence rate of the pre-period (pre-period IR as reference), pre-early post and pre-late post IR ratios with 95% confidence interval (CI) of the top 10 serotypes of the pre-period among \<5 and ≥50 years old, Austria, January, 2009-February, 2017.
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  ----------------------------------------------------------------------------------------------------------------------------------
  Age- group   pre-period rank   Serotype        Group    reference\            Early post-period IRR (95% CI)   Late post-period\
                                                          pre-period IR/10^6^                                    IRR (95% CI)
  ------------ ----------------- --------------- -------- --------------------- -------------------------------- -------------------
  **\<5**      1                 14              VT       1.06                  0.59 (0.23; 1.51)                0.19 (0.04; 0.82)

               2                 3               Non-VT   0.64                  0.33 (0.07; 1.51)                0.78 (0.26; 2.32)

               3                 19A             Non-VT   0.42                  0.73 (0.18; 2.93)                1.87 (0.65; 5.38)

               4                 18C             VT       0.35                  0.29 (0.03; 2.51)                \-

               5                 1               VT       0.28                  0.73 (0.13; 4.00)                0.35 (0.04; 3.13)

               6                 7F              VT       0.28                  0.73 (0.13; 4.00)                0.70 (0.13; 3.83)

               7                 11A             Non-VT   0.21                  \-                               \-

               8                 19F             VT       0.21                  0.98 (0.16; 5.84)                0.47 (0.05; 4.49)

               9                 6A              Non-VT   0.21                  0.98 (0.16; 5.84)                \-

               10                6B              VT       0.21                  0.49 (0.05; 4.69)                0.47 (0.05; 4.49)

                                 All serotyped            5.44                  0.61 (0.40; 0.92)                0.66 (0.44; 0.97)

  **≥50**      1                 3               Non-VT   1.08                  1.30 (1.00; 1.68)                1.97 (1.56; 2.48)

               2                 14              VT       0.48                  0.55 (0.33; 0.92)                0.61 (0.37; 0.98)

               3                 7F              VT       0.42                  0.76 (0.47; 1.23)                0.44 (0.24; 0.78)

               4                 19A             Non-VT   0.34                  1.17 (0.72; 1.88)                1.63 (1.05; 2.52)

               5                 19F             VT       0.27                  0.37 (0.17; 0.81)                0.45 (0.22; 0.91)

               6                 4               VT       0.26                  0.91 (0.51; 1.63)                0.74 (0.40; 1.36)

               7                 6A              Non-VT   0.26                  0.63 (0.32; 1.20)                0.55 (0.28; 1.09)

               8                 22F             Non-VT   0.24                  0.91 (0.49; 1.68)                1.90 (1.15; 3.15)

               9                 9N              Non-VT   0.21                  1.15 (0.63; 2.12)                1.22 (0.68; 2.21)

               10                9V              VT       0.18                  0.49 (0.21; 1.15)                1.00 (0.51; 1.96)

                                 All serotyped            5.79                  1.03 (0.92; 1.16)                1.28 (1.14; 1.43)
  ----------------------------------------------------------------------------------------------------------------------------------
